CSI Market
Sign In | Register

Trisalus Life Sciences Inc (TLSI) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access TLSI quarterly Cash Flow →
Tracking cash flow results across Trisalus Life Sciences Inc to Dec 31 2021 helps illustrate how Dec 31 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-39.23
Depreciation & amortization0.63
Amortization of Other Assets1.05
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability2.74
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.97
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.12
Share-based Compensation9.13
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.80
Fair Value Adjustment Of Warrants Liability-
Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party-
Gain Loss On Equity Issuance-
Gain Loss On Milestone Payment For Asset Acquistion-
Impairment Of Intangible Assets Excluding Goodwill-
Operating Lease Right Of Use Asset Amortization Expense0.43
Increase Decrease In Operating Lease Liability0.16
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-1.63
Increase (Decrease) in Accounts Payable and Accrued Liabilities2.02
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.84
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.96
Discontinued operations0.00
Net Cash flow from Operating Activities-18.01
Investing Activities
Capital Expenditures-0.92
Sale of Capital Items0.08
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments For Assets Acquisition Milestone-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.84
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.52
Long-term debt - borrowings10.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock21.37
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits Outstanding0.01
Other financing activities net0.00
Other net-8.88
Net Proceeds From Initial Public Offering-
Proceeds From Related Party Debt Convertible Promissory Note-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents8.88
Proceeds From Refundable Prepayments For Preferred Stock-
Proceeds From Reverse Recapitalization-
Payments Of Reverse Recapitalization Transaction Costs-
Finance Lease Principal Payments-0.08
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities30.76
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-18.85
Total Cash Flow11.91
4 historic quarters locked

Sign in to unlock the full Trisalus Life Sciences Inc cash flow history.

Sign In Create Free Account

About Trisalus Life Sciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-015163

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document